Organon & Co (OGN) concluded trading on Thursday at a closing price of $14.96, with 3.44 million shares of worth about $51.47 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.54% during that period and on March 13, 2025 the price saw a loss of about -0.27%. Currently the company’s common shares owned by public are about 257.80M shares, out of which, 257.25M shares are available for trading.
Stock saw a price change of 0.67% in past 5 days and over the past one month there was a price change of 0.07%. Year-to-date (YTD), OGN shares are showing a performance of 0.27% which decreased to -18.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.87 but also hit the highest price of $23.10 during that period. The average intraday trading volume for Organon & Co shares is 3.58 million. The stock is currently trading -1.86% below its 20-day simple moving average (SMA20), while that difference is down -2.88% for SMA50 and it goes to -17.08% lower than SMA200.
Organon & Co (NYSE: OGN) currently have 257.80M outstanding shares and institutions hold larger chunk of about 82.43% of that.
The stock has a current market capitalization of $3.86B and its 3Y-monthly beta is at 0.68. PE ratio of stock for trailing 12 months is 4.49, while it has posted earnings per share of $3.33 in the same period. Its PEG reads 5.16 and has Quick Ratio of 1.11 while making debt-to-equity ratio of 19.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OGN, volatility over the week remained 4.21% while standing at 4.53% over the month.
Stock’s fiscal year EPS is expected to drop by -6.56% while it is estimated to increase by 7.77% in next year. EPS is likely to grow at an annualized rate of 0.87% for next 5-years, compared to annual growth of -23.49% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on September 06, 2024 offering an Underweight rating for the stock and assigned a target price range of between $18 and $20 to it. Coverage by Goldman stated Organon & Co (OGN) stock as a Neutral in their note to investors on November 03, 2023, suggesting a price target of $16 for the stock. On September 21, 2023, Barclays Initiated their recommendations, while on March 16, 2023, Raymond James Initiated their ratings for the stock with a price target of $33. Stock get an Underperform rating from BofA Securities on October 14, 2022.
